Mark Feitelson

CSO, Co-Founder @ SFA Therapeutics

Mark Feitelson, CSO and Co-Founder, has published significant research on 'Short-chain fatty acids in cancer pathogenesis' and is leading the development of SFA-002, a promising drug for psoriasis showing positive results in clinical trials.

Mark Feitelson, CSO, Co-Founder

Mark Feitelson serves as the Chief Scientific Officer (CSO) and Co-Founder of his organization. His role involves spearheading scientific research and development efforts, with a focus on innovative therapeutic solutions. Feitelson's contributions are instrumental in advancing the organization's objectives in the medical and healthcare sector.

Mark Feitelson Published Work

Mark Feitelson has made significant contributions to scientific literature, including an article titled 'Short-chain fatty acids in cancer pathogenesis'. This work explores the role of short-chain fatty acids in the development and progression of cancer, shedding light on critical biochemical pathways and mechanisms. Such publications enhance the scientific community's understanding and drive further research in this field.

SFA-002 Phase 1b Clinical Trial for Psoriasis

Mark Feitelson announced positive results from the SFA-002 Phase 1b clinical trial for the treatment of mild-to-moderate chronic plaque psoriasis. This open-label prospective study demonstrated that SFA-002 acts on multiple therapeutic pathways, providing an immunomodulatory effect by down-regulating levels of pro-inflammatory cytokines involved in the pathogenesis of psoriasis. The trial reported no related adverse events or toxicities during the treatment period and follow-up, indicating a favorable safety profile. The second cohort of this trial is ongoing, with results anticipated by the end of 2023.

Safety and Efficacy of SFA-002 in Psoriasis Treatment

SFA-002 has shown the potential to be disease-modifying, delivering durable responses and an excellent safety profile in the treatment of psoriasis. According to Dr. Daniel Sauder, SFA-002 is an incredibly safe oral drug with high efficacy, highlighting its potential importance in psoriasis treatment. The drug acts on multiple therapeutic pathways and provides significant immunomodulatory effects, contributing to its promising therapeutic profile.

report flag Report inaccurate information

People similar to Mark Feitelson

Ira C. Spector, CEO and Co-Founder of SFA Therapeutics, has successfully led the Phase 1b clinical trial of SFA-002 for psoriasis, showing no adverse events and high efficacy.

Mike Moyer

Investor Relations @ SFA Therapeutics

Mike Moyer is an Investor Relations professional at LifeSci Advisors, involved in significant financing and clinical trial projects for psoriasis treatment.